FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285799505> ?p ?o ?g. }

• W4285799505 abstract "Studies suggest that immune checkpoint inhibitors may represent a promising strategy for boosting immune responses and improving the antitumor activity of standard therapies in patients with relapsed/refractory hematologic malignancies.Phase 1/2 FUSION NHL 001 was designed to determine the safety and efficacy of durvalumab, an anti-programmed death ligand 1 (PD-L1) antibody, combined with standard-of-care therapies for lymphoma or chronic lymphocytic leukemia (CLL).The primary endpoints were to determine the recommended phase 2 dose of the drugs used in combination with durvalumab (durvalumab was administered at the previously recommended dose of 1500 mg every 4 weeks) and to assess safety and tolerability. Patients were enrolled into one of four arms: durvalumab monotherapy (Arm D) or durvalumab in combination with lenalidomide ± rituximab (Arm A), ibrutinib (Arm B), or rituximab ± bendamustine (Arm C). A total of 106 patients with relapsed/refractory lymphoma were enrolled. All but two patients experienced at least one treatment-emergent adverse event (TEAE); those not experiencing a TEAE were in Arm C (diffuse large B-cell lymphoma [DLBCL]) and Arm D (DLBCL during the durvalumab monotherapy treatment period). No new safety signals were identified, and TEAEs were consistent with the respective safety profiles for each study treatment. Across the study, patients with follicular lymphoma (FL; n = 23) had an overall response rate (ORR) of 59%; ORR among DLBCL patients (n = 37) was 18%. Exploratory biomarker analysis showed that response to durvalumab monotherapy or combination therapy was associated with higher interferon-γ signature scores in patients with FL (p = .02).Durvalumab as monotherapy or in combination is tolerable but requires close monitoring. The high rate of TEAEs during this study may reflect on the difficulty in combining durvalumab with full doses of other agents. Durvalumab alone or in combination appeared to add limited benefit to therapy." @default.
• W4285799505 created "2022-07-19" @default.
• W4285799505 creator A5002445407 @default.
• W4285799505 creator A5004152557 @default.
• W4285799505 creator A5008943992 @default.
• W4285799505 creator A5010450706 @default.
• W4285799505 creator A5013112899 @default.
• W4285799505 creator A5014942120 @default.
• W4285799505 creator A5015529386 @default.
• W4285799505 creator A5016122215 @default.
• W4285799505 creator A5019034145 @default.
• W4285799505 creator A5025865972 @default.
• W4285799505 creator A5027118202 @default.
• W4285799505 creator A5031977714 @default.
• W4285799505 creator A5054145913 @default.
• W4285799505 creator A5054231625 @default.
• W4285799505 creator A5059022907 @default.
• W4285799505 creator A5064738578 @default.
• W4285799505 creator A5069105295 @default.
• W4285799505 creator A5082045927 @default.
• W4285799505 creator A5082078478 @default.
• W4285799505 creator A5090442154 @default.
• W4285799505 date "2022-07-19" @default.
• W4285799505 modified "2023-10-17" @default.
• W4285799505 title "Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The <scp>FUSION NHL</scp> 001 trial" @default.
• W4285799505 cites W1135493307 @default.
• W4285799505 cites W1955732360 @default.
• W4285799505 cites W2108206643 @default.
• W4285799505 cites W2119147717 @default.
• W4285799505 cites W2121770645 @default.
• W4285799505 cites W2125616358 @default.
• W4285799505 cites W2142099365 @default.
• W4285799505 cites W2142604595 @default.
• W4285799505 cites W2145785161 @default.
• W4285799505 cites W2152239989 @default.
• W4285799505 cites W2154066874 @default.
• W4285799505 cites W2160834915 @default.
• W4285799505 cites W2208577333 @default.
• W4285799505 cites W2412725897 @default.
• W4285799505 cites W2484191411 @default.
• W4285799505 cites W2560367415 @default.
• W4285799505 cites W2598700764 @default.
• W4285799505 cites W2609973112 @default.
• W4285799505 cites W2745624257 @default.
• W4285799505 cites W2753065806 @default.
• W4285799505 cites W2767931551 @default.
• W4285799505 cites W2787863642 @default.
• W4285799505 cites W2801456259 @default.
• W4285799505 cites W2910063137 @default.
• W4285799505 cites W2925270992 @default.
• W4285799505 cites W4285799505 @default.
• W4285799505 doi "https://doi.org/10.1002/cnr2.1662" @default.
• W4285799505 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35852004" @default.
• W4285799505 hasPublicationYear "2022" @default.
• W4285799505 type Work @default.
• W4285799505 citedByCount "3" @default.
• W4285799505 countsByYear W42857995052016 @default.
• W4285799505 countsByYear W42857995052022 @default.
• W4285799505 countsByYear W42857995052023 @default.
• W4285799505 crossrefType "journal-article" @default.
• W4285799505 hasAuthorship W4285799505A5002445407 @default.
• W4285799505 hasAuthorship W4285799505A5004152557 @default.
• W4285799505 hasAuthorship W4285799505A5008943992 @default.
• W4285799505 hasAuthorship W4285799505A5010450706 @default.
• W4285799505 hasAuthorship W4285799505A5013112899 @default.
• W4285799505 hasAuthorship W4285799505A5014942120 @default.
• W4285799505 hasAuthorship W4285799505A5015529386 @default.
• W4285799505 hasAuthorship W4285799505A5016122215 @default.
• W4285799505 hasAuthorship W4285799505A5019034145 @default.
• W4285799505 hasAuthorship W4285799505A5025865972 @default.
• W4285799505 hasAuthorship W4285799505A5027118202 @default.
• W4285799505 hasAuthorship W4285799505A5031977714 @default.
• W4285799505 hasAuthorship W4285799505A5054145913 @default.
• W4285799505 hasAuthorship W4285799505A5054231625 @default.
• W4285799505 hasAuthorship W4285799505A5059022907 @default.
• W4285799505 hasAuthorship W4285799505A5064738578 @default.
• W4285799505 hasAuthorship W4285799505A5069105295 @default.
• W4285799505 hasAuthorship W4285799505A5082045927 @default.
• W4285799505 hasAuthorship W4285799505A5082078478 @default.
• W4285799505 hasAuthorship W4285799505A5090442154 @default.
• W4285799505 hasBestOaLocation W42857995052 @default.
• W4285799505 hasConcept C121608353 @default.
• W4285799505 hasConcept C126322002 @default.
• W4285799505 hasConcept C143998085 @default.
• W4285799505 hasConcept C197934379 @default.
• W4285799505 hasConcept C203014093 @default.
• W4285799505 hasConcept C2776999253 @default.
• W4285799505 hasConcept C2777058707 @default.
• W4285799505 hasConcept C2777701055 @default.
• W4285799505 hasConcept C2777742743 @default.
• W4285799505 hasConcept C2777938653 @default.
• W4285799505 hasConcept C2778375690 @default.
• W4285799505 hasConcept C2778461978 @default.
• W4285799505 hasConcept C2779338263 @default.
• W4285799505 hasConcept C2780030458 @default.
• W4285799505 hasConcept C2780653079 @default.
• W4285799505 hasConcept C71924100 @default.
• W4285799505 hasConceptScore W4285799505C121608353 @default.
• W4285799505 hasConceptScore W4285799505C126322002 @default.
• W4285799505 hasConceptScore W4285799505C143998085 @default.

• next